Prime Highlights:
- Bristol Myers Squibb has introduced Kopozgo, India’s first approved cardiac myosin inhibitor, offering a new treatment option for obstructive hypertrophic cardiomyopathy (oHCM).
- The launch addresses a major unmet medical need, with 2.8 million estimated oHCM patients in India, most currently undiagnosed.
Key Facts:
- Kopozgo (Mavacamten) received CDSCO import approval in March 2025, backed by successful Phase 3 trials EXPLORER-HCM and VALOR-HCM.
- Originally acquired through BMS’s $13.1 billion purchase of MyoKardia, the drug is marketed as Camzyos in the U.S., earning $602 million in 2024 with 161% growth.
Background
Bristol Myers Squibb (BMS) has launched its heart therapy, Kopozgo, in India, hoping to offer a new cure to obstructive hypertrophic cardiomyopathy (oHCM). The active ingredient Mavacamten is available in the oral, selective cardiac myosin inhibitor, the first of its kind to be approved in India for this condition.
oHCM is a disease that occurs in approximately 1 per 500 individuals worldwide, with an approximate of 2.8 million possible patients in India, of which the majority have remained undiagnosed. In contrast to the conventional drugs used in the treatment, such as beta blockers and calcium channel blockers, Kopozgo can treat the underlying cause of the disease and increase the performance of the heart, and decrease the symptoms.
The launch follows an import license from the Central Drugs Standard Control Organisation (CDSCO) in March. Approval was supported by Phase 3 studies, EXPLORER-HCM and VALOR-HCM, which confirmed the drug’s safety and effectiveness. Some patients experienced a temporary drop in heart pumping ability (ejection fraction), but all recovered after pausing treatment.
Sanjay Sharma, General Manager and MD of BMS India, said, “With the launch of Kopozgo in India, patients now have a promising first-in-class therapy, offering doctors a new option to meet unmet treatment needs.”
BMS acquired the therapy through its $13.1 billion purchase of MyoKardia in 2020. The drug was approved by the US FDA in 2022 and is sold as Camzyos in the United States. In 2024, Camzyos achieved net sales of $602 million, marking a 161% rise over the previous year. BMS is positioning Kopozgo as a potential blockbuster brand in India.
